Market Research Logo

Clinuvel Pharmaceuticals Ltd (CUV) - Financial and Strategic SWOT Analysis Review

Clinuvel Pharmaceuticals Ltd (CUV) - Financial and Strategic SWOT Analysis

- Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Clinuvel Pharmaceuticals Ltd (Clinuvel Pharmaceuticals) is a biopharmaceutical company which focuses on the development of drugs for the treatment of severe skin disorders. Its lead product candidate, Scenesse (afamelanotide) is a first-in-class drug targeting erythropoietic protoporphyria (EPP). Scenesse is aimed to provide skin protection against UV radiation (UVR) as it stimulates the body’s natural ability to produce melanin, the dark pigment of the skin known to have photoprotective properties. The company has operations in Australia, Switzerland and the US. Clinuvel Pharmaceuticals is headquartered in Melbourne, Victoria, Australia.

Clinuvel Pharmaceuticals Ltd Key Recent Developments

Oct 30,2017: Clinuvel Pharmaceuticals: Appendix 4C
Oct 04,2017: Elie Ishag to Retire from Clinuvel Board
Jul 31,2017: Clinuvel Pharmaceuticals: Quarterly Cashflow report for the period ended 30 June 2017
Apr 28,2017: Clinuvel Pharmaceuticals: Appendix 4C - Quarterly report
Oct 24,2016: CLINUVEL relocates Melbourne office

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Clinuvel Pharmaceuticals Ltd - Key Facts
Clinuvel Pharmaceuticals Ltd - Key Employees
Clinuvel Pharmaceuticals Ltd - Key Employee Biographies
Clinuvel Pharmaceuticals Ltd - Major Products and Services
Clinuvel Pharmaceuticals Ltd - History
Clinuvel Pharmaceuticals Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Clinuvel Pharmaceuticals Ltd - Business Description
Clinuvel Pharmaceuticals Ltd - SWOT Analysis
SWOT Analysis - Overview
Clinuvel Pharmaceuticals Ltd - Strengths
Clinuvel Pharmaceuticals Ltd - Weaknesses
Clinuvel Pharmaceuticals Ltd - Opportunities
Clinuvel Pharmaceuticals Ltd - Threats
Clinuvel Pharmaceuticals Ltd - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Clinuvel Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Clinuvel Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Clinuvel Pharmaceuticals Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
Oct 04, 2017: Elie Ishag to Retire from Clinuvel Board
Jul 31, 2017: Clinuvel Pharmaceuticals: Quarterly Cashflow report for the period ended 30 June 2017
Apr 28, 2017: Clinuvel Pharmaceuticals: Appendix 4C - Quarterly report
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Clinuvel Pharmaceuticals Ltd, Key Facts
Clinuvel Pharmaceuticals Ltd, Key Employees
Clinuvel Pharmaceuticals Ltd, Key Employee Biographies
Clinuvel Pharmaceuticals Ltd, Major Products and Services
Clinuvel Pharmaceuticals Ltd, History
Clinuvel Pharmaceuticals Ltd, Other Locations
Clinuvel Pharmaceuticals Ltd, Subsidiaries
Clinuvel Pharmaceuticals Ltd, Key Competitors
Clinuvel Pharmaceuticals Ltd, Ratios based on current share price
Clinuvel Pharmaceuticals Ltd, Annual Ratios
Clinuvel Pharmaceuticals Ltd, Annual Ratios (Cont...1)
Clinuvel Pharmaceuticals Ltd, Interim Ratios
Clinuvel Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Clinuvel Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Clinuvel Pharmaceuticals Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Clinuvel Pharmaceuticals Ltd, Performance Chart (2013 - 2017)
Clinuvel Pharmaceuticals Ltd, Ratio Charts
Clinuvel Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Clinuvel Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report